Theravance Biopharma, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Theravance Biopharma, Inc. (TBPH) had Debt Securities, Available-for-sale, Unrealized Loss Position of $187.49 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $187.49M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $116.08M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $41.83M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $42.16M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position | Debt Securities, Available-for-sale, Unrealized Loss Position as first filed |
|---|---|---|
| 2026-06-30 | $187.49M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $116.08M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $41.83M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $42.16M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $51.52M 10-Q · filed 2025-08-13 | |
| 2024-12-31 | $23.00M 10-K · filed 2026-03-23 | |
| 2024-06-30 | $58.70M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $49.27M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $57.88M 10-Q · filed 2024-11-14 | |
| 2023-09-30 | $62.32M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $61.85M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $45.88M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $37.28M 10-K · filed 2024-03-01 | $37.28M 10-K · filed 2023-03-01 |
| 2022-09-30 | $77.25M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $45.56M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $63.15M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $35.02M 10-K · filed 2023-03-01 | |
| 2021-03-31 | $5.01M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $44.42M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $15.09M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $59.97M 10-Q · filed 2020-08-10 | |
| 2019-12-31 | $33.64M 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |